GCG and Parkinson disease: Through this combined mechanistic, translational, and clinical framework, the review extends beyond previous summaries of GLP-1 agonists and provides a comprehensive foundation for the rational development and optimization of incretin-based neuroprotective strategies in Parkinson’s disease.